Erlotinib

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Erlotinib (ncit:C65530)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Bevacizumab, Erlotinib